Rallybio Corporation (RLYB)
Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
16. 07
-0.16
-0.99%
$
76.98M Market Cap
- P/E Ratio
- Div Yield
54,448 Volume
-1.55 Eps
$ 16.23
Previous Close 
Want to track RLYB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Seekingalpha | 2 days ago
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Seekingalpha | 3 months ago
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
Zacks | 1 year ago
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
Rallybio (RLYB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 1 year ago
